Islet transplantation 30 years after the first transplants

Area of Science:

• Immunology
• Endocrinology
• Transplantation

Background:

• Clinical islet allotransplantation for type 1 diabetes mellitus (T1DM) has existed for 30 years.
• Current indications are limited to select patients with brittle T1DM.
• Immunosuppression remains a significant challenge, alongside islet production, engraftment, and long-term function.

Purpose of the Study:

• To review current strategies and future directions in islet allotransplantation for T1DM.
• To identify areas for improvement in islet production, engraftment, and immunosuppression.
• To discuss the potential of beta cell progenitor co-transplantation.

Main Methods:

• Review of existing literature and clinical trial data on islet allotransplantation.
• Analysis of strategies to enhance pancreas digestion and islet purification.
• Evaluation of methods to improve islet engraftment, reduce hypoxia, and mitigate inflammatory responses.

Main Results:

• Progress has been made in improving islet allotransplantation success rates.
• Strategies to enhance islet yield and engraftment are under investigation.
• Co-transplantation with beta cell progenitors is being explored to prolong graft survival.

Conclusions:

• Islet allotransplantation holds therapeutic potential for T1DM but requires further scientific and economic advancements.
• Addressing immunosuppression burden and optimizing the procedure are crucial for broader clinical application.
• Future clinical trials are anticipated to assess novel strategies and improve patient outcomes.